New Delhi: Minister of External Affairs Dr S Jaishankar on Wednesday welcomed the decision of the World Health Organization (WHO) to provide approval for Emergency Use (EUL) for Covid-19 Bharat Biotech vaccines based in Hyderabad, Covaxin.
“Welcome @ Who’s decision to provide a list of emergency use to #Covaxin.
It facilitates trips for many Indian citizens and contributes to vaccine equity.
Also global recognition to PM @ narendramodi about #atmanirbharbharat is happier,” Jaisankar tweeted.
The World Health Organization (WHO) has issued an emergency use listing for the original Indian vaccine, adding a vaccine portfolio that developed validated by who for prevention of Covid-19.
WHO said in the tweet that the technical advisory group, organized by the World Health Organization (WHO), has determined that Hyderabad-based Bharat Biotech Bharat Biotech vaccine meets the protection standards against Covid-19.
“Who gets an emergency use listing (EUL) to Covaxin® (developed by Bharat Biotech), adding a vaccine portfolio that develops validated by who for Prevention # Covid19,” said in a tweet.
“The technical advisory group, organized by who and consists of regulators from all over the world, has determined that the Covaxin vaccine meets protection standards for # Covid19, that the benefits of vaccines far exceed the risk and vaccine can be used,” it added.
Global Health Body said that the Covaxin vaccine was also reviewed by who the experts’ strategic advisors of immunization (wise), and recommended the use of this vaccine in two doses, with a four-week dose interval, in all groups of age 18 and above.
“The data available on vaccination of pregnant women with covaxin vaccines is not enough to assess the security or efficacy of vaccines in pregnancy; studies in pregnant women are planned, including pregnancy sub-studies and pregnancy registration,” said.